New AI Glasses for Dementia ‘Sees’ Objects With Labels Projected on Lenses to ‘Significantly’ Improve Lives

Carole Grieg testing the CrossSense AI glasses – SWNS

New AI glasses for people with dementia are able to project visual prompts onto the lenses to help folks live more independently—and they could be available in the UK in 2027.

The latest news comes after the glasses wowed both test patients in their homes and a panel of outside judges.

They can guide people living with early-stage dementia through daily activities by identifying common objects and providing audio commentary or answer questions while projecting visual prompts onto the lenses.

By asking gentle questions, the glasses’ AI companion, called ‘Wispy’, understands and learns a person’s unique way of doing things, with the AI adapting to each user’s needs as their dementia progresses.

Wispy will even talk through what to do when a person cannot remember a particular step in a process.

In test trials, three out of four patients reported a significant improvement to their quality of life, thanks to the glasses and Wispy’s tips developed from UK company CrossSense.

Warning appears on the lenses of the CrossSense AI glasses (GNN screenshot of SWNS/CrossSense video)

Spending over a decade creating and tweaking prototypes of the app and gadget, a team of AI engineers trained the glasses with dozens of everyday activities including getting dressed, managing household chores safely, making a cup of tea and interacting with loved ones.

The specs, which work with people’s prescription lens inserts and hearing aids, also capture the environment of the person living with dementia and the AI interprets that information to help the user to do the things that define independence.

“This includes feeling confident in their own home, taking good care of themselves, planning the day ahead, completing planned activities and hosting friends and family,” said the creators.

Screenshot of Wispy AI in the midst of interacting with user of theCrossSense AI glasses, discussing care of a houseplant (Still from SWNS video)

With a release date set for early 2027 in the UK, the inventors hope the specs, which weigh less than 3 ounces (75g), will be used by local authorities, care providers, and NHS hospital memory clinics.

Last week, the London-based team behind the technology, CrossSense, won the Longitude Prize on Dementia with its million dollar prize funded by the Alzheimer’s Society and Innovate UK.

The panel of international expert judges agreed that the winning solution was a genuine breakthrough technology with revolutionary potential for people living with dementia and their families.

CrossSense says the gadget includes a built-in battery that lasts for one hour, but also a portable power bank that can keep the glasses running all day long.

70-year-old Carole Grieg from London (pictured above), who founded a dementia support group called ForgetMeNots, tried the new glasses and is convinced they could help her fellow dementia patients maintain their independence.

“I thought it was an amazing concept, with the potential to provide real, reliable support for people like me, helping to compensate for the cognitive skills we gradually lose as dementia progresses.”

“For many of us, our world slowly becomes smaller as the condition progresses. Innovations like this offer real hope, and I know that as my own circumstances change, I will certainly be relying on them.”

Professor Fiona Carragher, chief research officer at Alzheimer’s Society admires the way the technology can develop its ‘intuitive personal support’.

“By anticipating people’s needs as their condition progresses, easing daily living challenges, and providing reassurance to families, this revolutionary tech will allow people with dementia to maintain their independence for longer, within the familiar environment of home.” New AI Glasses for Dementia ‘Sees’ Objects With Labels Projected on Lenses to ‘Significantly’ Improve Lives

Read More........→April 23, 2026

High-salt diet linked to faster memory decline in men: Study

(Representational photo; source: IANS)

Sydney, (IANS) A diet high in salt may accelerate memory decline in men, Australian research reveals, highlighting the importance of dietary choices in supporting brain health.

The study found that higher sodium intake may impair episodic memory, which enables people to recall personal experiences and past events, such as where you parked your car or your first day of school, said a statement from Australia's Edith Cowan University (ECU) released Wednesday.

Measuring baseline sodium intake and cognitive decline of 1,208 participants over 72 months, researchers found that men with higher sodium intake experienced faster episodic memory decline, while no link was seen in women.

While sodium serves several physiological functions and is inextricably linked to the maintenance of the body, high sodium consumption has consistently been associated with an increased risk of cardiovascular events and high blood pressure, according to the study published in Neurobiology of Ageing.

Lead researcher Samantha Gardener from ECU said that while the molecular mechanisms behind the process were not yet understood, it was thought that high sodium intake could contribute to inflammation in the brain, damage to blood vessels, and reduced blood flow to the brain.

Meanwhile, a recent Israeli study suggested that while memories themselves may fade, the explanations people give for why they remember events remain detailed and stable over time.

Researchers analysed the self-reported explanations of 421 participants using linguistic tools to track changes in content and detail. They found that while the ability to recall specific events declined over time, the depth and content of participants' justifications remained steady.

The frequency of these explanations and the types of words used were consistent, indicating they may serve as reliable markers of memory accuracy.

Subtle shifts in wording over time, however, suggest that a person's confidence in their memory may decrease as the event recedes into the past.The study, published in Communications Psychology, indicates that even when memories feel "fuzzy," the reasons people give for recalling them remain a relatively dependable way to assess their truthfulness. Still, legal and clinical professionals should note that confidence may waver, even if the justification itself remains strong. High-salt diet linked to faster memory decline in men: Study | MorungExpress | morungexpress.com

Read More........→April 16, 2026

Johns Hopkins Team Develops Therapeutic, Nasally-Delivered DNA Vaccine for Tuberculosis

Artist’s illustration of tuberculosis bacteria (TB) – credit, US CDC

A research team at Johns Hopkins Medicine is developing a nose-delivered inoculation against tuberculosis, the world’s leading cause of death from infectious disease.

The approach fuses two tuberculosis genes with the goal of directing the immune system to fight drug-tolerant bacterial survivors that can endure antibiotic treatment to spread another day.

The paper on the vaccine was published last week in the Journal of Clinical Investigation, where JH Medicine researchers were joined by colleagues from the Johns Hopkins Bloomberg School of Public Health.

TB is estimated by the World Health Organization (WHO) to be spread asymptomatically by around 2 billion people. In 2024 , WHO reported that TB was the leading cause of death from a single infectious disease.

In recent years, WHO has called for therapeutic vaccines that can be used alongside drug therapies to shorten TB treatment regimens and improve outcomes, particularly because long multidrug courses are difficult to complete, and drug-resistant TB strains continue to emerge. The vaccine described in the new Johns Hopkins study shows promise for meeting that need.

The new Johns Hopkins vaccine, says study lead author Styliani Karanika, MD, fuses two genes: relMtb and Mip3α, and is given through the nose to take advantage of 3 beneficial biological activities.

“Administered together with first-line TB drug therapy, our intranasal DNA fusion vaccine helped infected mice clear the disease bacteria faster, reduced lung inflammation, and prevented relapse after treatment ended,” says Karanika, a faculty member of the Johns Hopkins Center for Tuberculosis Research.

“The vaccine also helped the powerful TB drug combination of bedaquiline, pretomanid, and linezolid work better, suggesting it could be used with treatments against drug-resistant TB to help the body fight the disease, even hard-to-treat cases.”

Dr. Karanika explained that TB bacteria possess a gene—relMtb—that produces a protein called RelMtb—which together help the microbes survive hostile conditions such as antibiotic exposure, low oxygen, and nutrient limitation by entering a drug-tolerant persistent state.

Fusing relMtb with another gene called Mip3α produces a signal that attracts immature human dendritic cells. These cells pick up TB proteins and ‘present’ them to T cells, the immune cells that help coordinate a targeted attack on the TB bacteria.

“Finally, intranasal delivery focuses vaccination on the respiratory mucosa in the lungs where TB infection occurs, helping generate long-lasting localized T-cell immunity in the airways and lungs, along with systemic immune responses,” says Karanika.

By combining these strategies, the investigators aimed to strengthen immune activity directly in the respiratory tract, where transmission most commonly occurs.

In the mouse studies, this approach both improved the quantity and organization of dendritic and T-cells in the lungs, and generated immune responses both locally and systemically. The improved response included to two types of T-cells, CD4 (also known as helper T-cells) and CD8 (also known as killer T-cells).

One study strongpoint was that it included tests on primates: in this case, rhesus macaques. The researchers found that their nose-delivered DNA vaccine prompted measurable TB‑focused immune responses in blood and in the airways similar to what led to lower bacterial counts in the lungs of the mice they studied.

These responses persisted for at least 6 months, suggesting durability for the vaccine’s action.

“These nonhuman primate data are encouraging because they show that the Mip3α/relMtb vaccine can generate durable, antigen-stimulated immune responses in an animal model whose immune system more closely resembles that of humans,” said Dr. Karanika. “That gives us an important translational bridge between the mouse efficacy studies and the additional preclinical work needed before human trials.”

Readers may recoil from the notion of primate testing, but Old World Monkeys are very susceptible to TB, and in fact spread it between themselves just as we do. Research has shown that TB has been spread among humans as far back as 70,000 years, and followed our migration out of Africa and across Asia.The authors say their findings support a broader strategy of targeting surviving TB bacteria with immunotherapy, rather than relying solely on antibiotics to eliminate actively replicating bacteria. Because DNA vaccines are relatively stable and can be manufactured efficiently, they may offer practical advantages if this approach ultimately proves effective in humans. Johns Hopkins Team Develops Therapeutic, Nasally-Delivered DNA Vaccine for Tuberculosis

Read More........→April 15, 2026

AI-powered digital stethoscopes show promise in bridging screening gaps

(Photo: Eko Health, US) IANS

New Delhi, As tuberculosis (TB) continues as the deadliest infectious cause of deaths globally, a new study has shown that artificial intelligence (AI)-enabled digital stethoscopes can help fill critical screening gaps, especially in hard-to-reach areas.

In a commentary published in the journal Med (Cell Press), global experts contended that stethoscopes combined with digital technology and AI can be a better option against the challenges faced in screening programmes, such as under-detection, high cost, and inequitable access.

“AI-enabled digital stethoscopes have demonstrated promising accuracy and feasibility for detecting lung and cardiovascular abnormalities, with promising results in early TB studies. Training and validation in diverse, high-burden settings are essential to explore the potential of this tool further,” said corresponding author Madhukar Pai from McGill University, Canada, along with researchers from the UAE, Germany, and Switzerland.

Despite advancements in screening and diagnostic tools, an estimated 2.7 million people with TB were missed by current screening programmes, as per data from the World Health Organization (WHO). Routine symptom screening is also likely to miss people with asymptomatic or subclinical TB.

While the WHO recently recommended several AI-powered computer-aided detection (CAD) software, as well as ultra-portable radiography hardware, higher operating costs and upfront hardware act as a deterrent.

This particularly appeared difficult in primary care settings and or among pregnant women due to radiation concerns.

At the same time, AI showed significant potential for screening, including applications beyond CAD of TB from radiographs, said the researchers.

“One application of AI for disease screening is to interpret acoustic (sound) biomarkers of disease, with potential to identify sounds that appear nonspecific or are inaudible to the human ear,” they added, while highlighting the potential of AI in detecting and interpreting cough biomarkers and lung auscultation to analyse breath sounds.

Studies from high-TB burden countries, including India, Peru, South Africa, Uganda, and Vietnam, highlighted that AI-enabled auscultation could hold promise as a TB screening and triage tool.

"AI digital stethoscopes may become useful alternatives to imaging-based approaches for TB screening, with the potential to democratise access to care for populations underserved by radiography," the researchers said."Importantly, AI digital stethoscopes offer a scalable, low-cost, and person-centered tool that could bring us closer to reaching TB case finding goals," they added. AI-powered digital stethoscopes show promise in bridging screening gaps | MorungExpress | morungexpress.com

Read More........→April 12, 2026

India launches world’s 1st clinical trial to test Ayurveda with TB treatment

(File Photo/IANS)

New Delhi, (IANS) On the occasion of World Tuberculosis Day, India announced the world’s first clinical study to scientifically evaluate Ayurveda as an adjunct to standard Anti-Tuberculosis Treatment (ATT), the government said on Tuesday.

The collaborative clinical study between the Department of Biotechnology and the Ministry of Ayush will enrol 1,250 newly diagnosed tuberculosis patients across eight institutions to evaluate Ayurveda as an adjunct to standard treatment, focusing on body weight, nutritional outcomes, disease progression, quality of life, safety, and tolerability.

Union MoS for Science & Technology Jitendra Singh said the study reflects the spirit of “whole-of-science,” approach by integrating biotechnology and Ayurveda; “whole-of-government” approach through collaboration between ministries.

DG, CCRAS, Prof. Vaidya Rabinarayan Acharya said the initiative has progressed through consultations, protocol finalisation, and approvals.

Director, BRIC-NII, Dr. Debasisa Mohanty said the study will examine tuberculosis-associated cachexia as an immune-metabolic condition, using advanced tools such as DEXA, MRI, immune profiling, metabolomics, and single-cell RNA sequencing to understand changes in body composition, immune function, and energy metabolism.

It is aimed to assess how integrative interventions influence recovery and long-term outcomes, the statement from the Ministry of Science & Technology said.

Minister Jitendra Singh said India, which accounts for nearly 25 per cent of the global TB burden, saw a 21 per cent drop in a decade in tuberculosis incidence to about 187 cases per 1,00,000 population in 2024.

“The decline in TB incidence is an outcome of India’s dedicated and innovative efforts. Through a collective spirit, we will keep working towards a TB-free India,” he quoted Prime Minister Narendra Modi.

India has adopted an ambitious and accelerated pathway towards TB elimination, strengthening early diagnosis, universal drug susceptibility testing, digital adherence technologies, and patient-centric care under the National TB Elimination Programme, the minister said.

He pointed out the reciprocal relationship between TB and conditions such as diabetes, where each can aggravate the other, making integrated approaches essential for effective disease management.He also referred to the RePORT India programme, one of the largest TB research consortia, with over 4,500 enrolled TB patients and over 5,000 household contacts, generating evidence relevant for global policy frameworks, including WHO guidelines on nutrition and tuberculosis. India launches world’s 1st clinical trial to test Ayurveda with TB treatment | MorungExpress | morungexpress.com

Read More........→April 02, 2026

Surgeons Perform First-Ever Surgery for Critically-Endangered Monkey Weeks Before She Gave Birth

Chester Zoo via SWNS

GNN often stays abreast of births among the Chester Zoo’s incredibly diverse residents of rare and endangered species, but few have ever been cuter or rarer than this Roloway monkey.

Chester Zoo is one of only two places in the UK that Roloway monkeys can be found, a spokesman said, and the breeding population there supports the animal as conservationists ponder what to do to ensure it can survive in its West African home.

The mother is named Masaya, and before the 15-year-old primate gave birth to a daughter named Lagertha, she was the first ever Roloway monkey to undergo surgery in captivity—to remove a golf-ball sized abscess from her foot.

Masaya had to have one toe amputated during the procedure, which was done at the University of Liverpool’s Small Animal Teaching Hospital.

“Masaya is a very experienced mom and she’s parenting magnificently,” said

Zoe Edwards, primate keeper at Chester Zoo. “The fact Masaya’s foot has healed so well is a huge relief. If she’d had a [full] amputation, we’d have been left with real questions about whether she could hold her offspring or continue with her normal behaviors.”

Roloway monkeys originate from West Africa and are listed as Critically-Endangered by the International Union for Conservation of Nature (IUCN). Once common in the lush rainforests of Ghana and the Ivory Coast, the Roloway monkey now survives only in isolated pockets of old-growth forest.

The baby’s name is Lagertha – credit, Chester Zoo via SWNS

Masaya at the Liverpool Vet. Hospital where she underwent surgery – credit, Chester Zoo via SWNS

Chester Zoo witnessed the first birth of a Roloway monkey in captivity in 2020, and Lagertha is the 3rd to be born since then. Edwards said it marked an important moment in the species’ conservation. There are only a few breeding females in zoos in Europe, and only one other in England at the Yorkshire Wildlife Park.

Masaya had experienced recurring problems with her foot since she came to the zoo in 2023. It was determined to be an abscess, and when the swelling worsened in 2025, the decision was made to take Masaya to Liverpool for a CT scan.

“It’s not every day you take a monkey to vet school,” said Charlotte Bentley, Veterinary Officer at the zoo’s Animal Health Center. “Following the scan, we decided an operation was the way forward.”

According to the New England Primate Conservancy, the Roloway monkey is now considered one of the most urgently threatened primates in the entire world. A big-bodied monkey, they have been hunted to such small populations that, ironically, they’re now considered too uneconomical to pursue anymore, and so have inadvertently gained a short respite from poaching.

he conservancy admits that the most likely chance for survival is for breeding programs like the one at Chester to continue the propagation of the species until such a time as their native forests in Ghana and the Ivory Coast can be appropriately and reliably protected from poachers and logging. Surgeons Perform First-Ever Surgery for Critically-Endangered Monkey Weeks Before She Gave Birt

Read More........→March 22, 2026

Couples share 30% of their gut bacteria. Here’s how that may affect health

Conor Meehan, Nottingham Trent University and Janelle Mwerinde, Nottingham Trent University

When living with a partner, you might be sharing more than just the same home, lifestyle and interests. You might also share various microscopic organisms residing on and in you.

This community of microorganisms, which consists of mainly bacteria, viruses and fungi, is known collectively as the human microbiome. The various microbiomes found throughout the body all play an important role in health.

From birth, the human microbiome is shaped by our interactions with our mother, who introduces diverse microorganisms that build our immune and digestive systems. As we get older, social interactions with our close community continue influencing this delicate ecosystem.

The people we live with have huge influence on what microbes we have in our microbiome. In fact, it’s thought that partners share around 30% of their resident microbes in the gut alone.

But it isn’t just the microbes in your gut that may be similar to your partner. The microbes in many other parts of the body may also be shared with your loved one – and this could potentially affect your health.

Gut microbiome

Diet and lifestyle are thought to have the greatest influence on the gut microbiome’s make-up. But studies on couples have found that living with your partner can also influence the microbiome.

Couples living together may share 13% to 30% of their gut bacteria. This was true even when diet (which many couples share) was factored out. Research also shows that couples who live together have greater microbial diversity compared to people who live alone.

This is good news for couples who co-habitate, as a more diverse gut microbiome is correlated with lower risk of irritable bowel syndrome, cardiovascular diseases and potentially high blood sugar.

But it might not all be good news. Research shows that some of the bacterial species couples share can have varying effects on health.

Take the bacteria from the Ruminococcus family. While some species of Ruminoccocus benefit health, others have been linked to negative health outcomes, including diabetes and irritable bowel syndrome.

So these bacteria may not always offer the same benefits in different demographics. This highlights the complexity of resident gut bacteria and their health impacts.

Oral microbiome

Sharing an oral microbiome with our partners might seem obvious considering we regularly exchange saliva when we kiss. A ten-second kiss alone can exchange up to 80 million bacteria. The more kisses a couple shares, the more shared salivary bacteria they will have.

Although most of these bacteria will quickly pass through our mouth and into our gut when we swallow saliva, research show that couples actually share many of the same longer-term tongue microbes that form the foundation of the oral microbiome. Research even suggests that 38% of the oral microbiome is shared in couples living together – compared to only 3% in couples who don’t live together.

Sharing this proportion of your oral microbiome could have many potential health effects.

A healthy oral microbiome is important for protecting against tooth decay and it has anti-inflammatory properties. Some researchers also suggest the oral microbiome’s health effects may extend as far as the gut and nervous system.

But some of the bacteria that couples tend to share may also have potentially harmful health effects.

Couples are more likely to have similar numbers of the bacteria Neisseria in their gut compared to single people. Neisseria can reside in the mouth for long periods of without causing disease.

Some Neisseria bacteria can be harmful and may cause meningitis. Yet some Neisseria bacteria actually fight against these meningitis-causing species, stopping them from overgrowing and causing harm.

So while you may want to avoid kissing someone when they’re poorly for obvious reasons, it turns out that a kiss even when you’re healthy can transfer all sorts of bacteria between the two of you.

More research is needed to really understand what overall effect sharing these bacteria with your partner has on health.

Skin microbiome

The skin microbiome is the most unique and personalised microbiome, tailored to each person. It’s even sometimes referred to as our microbial fingerprint.

Being the most exposed microbiome, the skin microbiome has evolved to be adaptable to external factors such as the climate and cosmetic products. No matter what, these bacteria work hard to remain at an equilibrium.

Close contact with our partners – and even pets – has a huge influence on what bacteria live on our skin. After comparing the gut and oral microbiome, researchers found the skin microbiome to be the most similar among couples.

It isn’t just the bacteria on your arms or hands that are shared, either. Research shows that couples shared 35% of the bacteria living on their feet, and around 17.5% of the bacteria on their eyelids.

You may not even need to touch your partner to have the same skin bacteria as them. Factors such as sleeping in the same bed and walking on similar surfaces are thought to explain why such a large proportion of our skin microbiome is similar.

This is because humans naturally shed bacteria in a similar way as dogs shed fur. We leave traces of our bacteria on everything we touch – and we also easily pick up bacteria from our environments.

The shared effect of living together on the skin microbiome is so great that researchers were able to use computer models to accurately predict 86% of cohabiting couples based off of their individual bacterial samples alone.

But while it’s clear that couples share much of the same skin microbiome, the health effect that this has is not currently known.

While sharing bacteria with your partner may sound alarming, there’s often no cause for concern. Bacteria teach our bodies how to fight infections, they help us digest foods and even produce key nutrients. The bacteria we share with our partners are often harmless and sometimes benefit our health rather than hindering it.

Conor Meehan, Associate Professor of Microbial Bioinformatics, Nottingham Trent University and Janelle Mwerinde, PhD Candidate, Skin Microbiology, Nottingham Trent University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read More........→March 20, 2026

AI could help us more accurately screen for breast cancer – new research

Sasun Bughdaryan/Unsplash Carolyn Nickson, University of Sydney; The University of Melbourne and Bruce Mann, The University of Melbourne

At least 20,000 Australian women are diagnosed with breast cancer each year. And more than 3,300 die from the disease.

To save women’s lives, we need to detect breast cancer early. Breast screening, which halves women’s risk of dying from breast cancer, is key to that.

A new Australian study published today in The Lancet Digital Health suggests AI could help improve how we screen for breast cancer.

How do we currently screen for breast cancer?

Since 1992, Australia has offered free breast X-rays, known as mammograms, every two years to women aged between 50 and 74. Just over half of eligible women participate.

Of the women found to have cancer, about 25% are diagnosed between the biennial screens. These “interval cancers” are often aggressive and, unfortunately, more likely to be fatal.

In some cases, a more sensitive screening test may have detected them earlier.

The role of AI

Australia’s BreastScreen program was established in response to several major clinical trials conducted between the 1960s and 1980s. The screening technology used by the program has not substantially changed since then.

Researchers are now exploring risk-adjusted screening, which tailors screening to women based on their risk, as a way to detect more cancers earlier. This may include programs offering different technologies for women at higher risk of developing breast cancer.

Currently, we generally assess cancer risk via questionnaires that help identify if a woman has any risk factors associated with breast cancer.

One risk factor is breast density which refers to how much glandular tissue is in the breast. As well as being a risk factor for breast cancer, the higher a woman’s breast density, the harder it is to detect cancer on a mammogram.

We can also use one-off genetic testing to identify women with a higher lifetime risk of developing breast cancer. This involves looking for high-risk gene mutations such as BRCA1 and BRCA2, which are associated with increased breast and ovarian cancer risk. Genetic testing can also help us estimate a person’s lifetime risk of developing breast cancer.

More recently, researchers have been investigating artificial intelligence (AI) as a new approach to assess breast cancer risk. A new Australian study, published in The Lancet Digital Health today, focused on a specific AI tool known as BRAIx.

What did the study involve? And what did it find?

This study used an AI tool, known as BRAIx, trained using BreastScreen Australia data to help radiologists assess mammograms.

The study assessed how well BRAIx predicted women’s risk of developing breast cancer in the next four years, among women who had a clear mammogram.

Of the 95,823 Australian women assessed, 1.1% (1,098) had developed breast cancer in the four years after they received a clear mammogram. Of the 4,430 Swedish women assessed, 6.9% had developed breast cancer within two years of a clear screen.

The study findings show that BRAIx scores were very useful for identifying women who were more likely to develop cancer one to two years after having a clear screen. Findings from the Australian dataset suggest BRAIx scores identified cancers found three to four years later, but with less accuracy.

These findings suggest BRAIx could help identify women who might benefit from additional tests. This may include an MRI (which uses a magnetic field to produce images of organs and tissue) or contrast-enhanced mammography (which uses an iodine dye to improve the visibility of a regular mammogram).

These findings reinforce a 2024 Swedish study that used an AI-based risk assessment to select women for additional testing. The researchers referred 7% of women to have a follow-up MRI, and 6.5% of were found to have cancers missed by mammograms.

Does the study have any limitations?

As with most studies, yes. Here are two.

• it’s difficult to compare BRAIx to genetic testing. This is because BRAIx is trained to find missed or emerging cancers over a four year period. In contrast, genetic testing identifies a person’s risk of developing cancer over their lifetime

• it might not use the best breast density data. This study found BRAIx more accurately predicts breast cancer risk compared to assessments based on breast density. But this breast density data was collected using a different tool to those used by the Breastscreen program. So this finding should be interpreted carefully.

So, where to from here?

The study adds to a growing body of evidence that AI risk assessment could help breast screening programs find cancers earlier.

BRAIx is now being trialled as part of the BreastScreen Victoria program, to help read mammograms. And other states are already using and evaluating different AI tools for reading mammograms.

So it may be time for Australia to conduct a national, independent review of these new tools. As part of a more risk-adjusted approach to breast screening, they could save lives.

Carolyn Nickson, Principal Research Fellow, Cancer Elimination Collaboration, University of Sydney; The University of Melbourne and Bruce Mann, Professor of Surgery, Specialist Breast Surgeon, The University of Melbourne

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read More........→March 10, 2026

Here’s why you might want to clean your headphones

Rina Wong (Fu), Curtin University

Whether it’s enjoying a podcast, listening to music or chatting on the phone, many of us spend hours a day using our headphones. One 2017 study of 4,185 Australians showed they used headphones on average 47–88 hours a month.

Health advice about headphones tends to focus on how loud sounds might affect our hearing. For example, to avoid hearing loss, the World Health Organization advises people to keep the volume at below 60% their device’s maximum and to use devices that monitor sound exposure and limit volume.

But apart from sound, what else is going in our ears? Using headphones – particularly in-ear versions such as earbuds – blocks the ear canal and puts the skin in contact with any dirt or bacteria they may be carrying.

Here’s what you need to know about keeping your ears clean and safe.

First, let’s take a look at your ear

Over-ear headphones cover the entire external ear – the elastic cartilage covered by skin that’s shaped to trap soundwaves. In-ear headphones (as well as hearing aids) are shaped to fit and cover the entrance to the external ear canal, which is called the concha.

Sound vibrations travel through the ear canal – which is S-shaped and a few centimetres long – to reach your ear drum.

Deeper parts of the ear canal produce earwax and oils. These help keep your skin healthy, hydrated and less vulnerable to infection.

Tiny hairs in the ear canal also help regulate temperature and keep foreign debris out. These hairs and earwax help trap and move small particles, shed skin and bacteria out of the ear canal.

Earwax is the ear’s self-cleaning method and we only tend to notice it when there’s too much.

Excessive buildup can block your hearing or even clog the mesh of your earpods. But don’t try to dig earwax out of your ears yourself. If you’re concerned, speak to a pharmacist or GP for advice.

How headphones can affect the ear’s bacteria

Healthy ear canals host a range of non-harmful microbes – mainly bacteria, but fungi and viruses too. They compete for space and nutrients, and this diversity makes it trickier for any potential pathogens (disease-causing microorganisms) to take hold.

But wearing headphones (and other in-ear devices such as hearing aids or ear plugs) may upset the balance between “good” and “bad” bacteria.

One 2024 study compared bacteria in the external ear canals of 50 people who used hearing aids and 80 who didn’t. The researchers found hearing-aid users – whose external ear canals are blocked for extended periods – had fewer types of bacteria than those who didn’t.

Another 2025 study looked at how using headphones (including over-ear, in-ear and on-ear) affected fungi and bacteria in the ear canal. It found using headphones was linked to a greater risk of ear infections, especially if people shared them.

This may because wearing headphones – especially in-ear devices – makes the external ear canal hotter and more humid. Trapped moisture is especially likely if you exercise and sweat while wearing headphones.

Higher humidity increases your risk of ear infection and discharge, including pus.

Wearing in-ear devices such as hearing aids or headphones for extended periods can also interfere with the ear’s natural “self-cleaning” function, aided by earwax.

So, what should I do?

Most of us need – or like – to wear headphones in our day-to-day routines. But for good ear health, it’s important to give your ears a break.

Allow your ear canals to “breathe” at different points throughout the day so they’re not constantly blocked and growing humid and hot.

You could also try bone conduction headphones. These don’t block the ear canal, because they transmit sound through your skull directly into the inner ear, without needing to block the ear canal. These can be expensive though. And while they allow our ears to breathe, high-intensity vibrations (high volume) can still damage hearing, so as with all headphones caution is required.

Other tips

Clean your devices regularly

Recommendations range from once a week to daily to after a physical workout.

For example, you can wipe them with a cloth or use a soft-bristled children’s toothbrush dampened with mildly soapy water. Blot dry with a paper towel and allow a few hours of drying before recharging or reuse.

But it’s best to follow your manufacturer’s guidelines. And don’t forget to clean the case and the body of your earbuds too.

Don’t use headphones when sick

If you have an ear infection, avoid using earphones as they may increase the temperature and humidity in your ear and slow recovery.

Watch for symptoms

If your ears become itchy, red or have discharge, stop using in-ear devices and seek medical advice.

Rina Wong (Fu), Research Fellow, Health Sciences, Curtin University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read More........→March 10, 2026

New Spray-on Powder Instantly Seals Life-Threatening Wounds in Battle or During Disasters

South Korean scientists win award for wound powder – SWNS

A spray-on powder that instantly seals life-threatening wounds could save thousands of lives, say scientists.

The new substance can help prevent excessive bleeding which is the leading cause of death due to injuries in war, according to a study.

The fast-acting powder that stops bleeding in just one second was developed by South Korean scientists who say it can also be applied in emergency hospital procedures.

The research team at the Korea Advanced Institute of Science and Technology (KAIST) in Daejeon, which included an Army Major, created the powder that rapidly forms a strong hydrogel barrier when sprayed directly onto a bullet wound.

The team designed the technology with real combat conditions in mind, and the direct involvement of an Army Major helped ensure its practical readiness.

Major Kyusoon Park, who is also a PhD candidate and served as a study co-author, said the substance not only allows “instant hardening” under extreme conditions like combat or disasters but also delivers high usability and storage stability.

“Until now, patch-type hemostatic agents widely used in medical fields have had limitations due to their flat structure and sensitivity to temperature and humidity.”

They cannot withstand pressure applied to the wound. Also, current powders that stop blood flow have limited functionality by physically absorbing blood to form a barrier, according to the study published in the journal Advanced Functional Materials.

Medical first aide equipment for combat care at Marine Corps Base Camp Lejeune – Credit: Navy Medicine via Unsplash

“The new AGCL powder reacts with cations, such as calcium in the blood, to turn into a gel state in one second, instantly sealing the wound,” said study co-leader Professor Steve Park.

“Furthermore, by forming a three-dimensional structure inside the powder, it can absorb blood amounting to more than seven times its own weight.”

“It shows superior sealing performance compared to commercial hemostatic agents—with a high adhesive strength and a level of pressure that can withstand being pressed strongly by hand.”

AGCL powder is composed entirely of naturally derived materials with an antibacterial effect of 99.9%.

It has a structure that combines biocompatible natural materials such as alginate and gellan gum—that react with calcium for fast gelation and physical sealing—and chitosan, which bonds with blood components to enhance chemical and biological hemostasis.

“In animal experiments, excellent tissue-regeneration effects, such as rapid wound recovery and promotion of blood vessel and collagen regeneration, were confirmed,” explained Prof. Park.

“In surgical liver injury experiments, the amount of bleeding and hemostasis time were significantly reduced compared to commercial methods.”

“It also maintains its performance for two years, even in room temperature and high humidity environments, possessing the advantage of being ready for immediate use in harsh environments.

“Although this is an advanced new material technology developed with national defense purposes in mind,” said Major Park, “it has great potential for emergency medicine, disaster sites, developing countries, and medically underserved areas.”“I started the research with a sense of mission to save even one more soldier—but I also hope this technology will be used as a life-saving technology in private medical fields.” New Spray-on Powder Instantly Seals Life-Threatening Wounds in Battle or During Disasters

Read More........→February 23, 2026

Highly Fatal Virus May Finally Be Treatable with First Vaccine–Clinical Trials Starting

The Nipah virus pictured in red – credit, US NIH

In January, India recorded a mini-outbreak of the Nipah virus, an often lethal disease spread by contact between humans and animals.

There was little that could be done for the victims, as no specialized treatment for Nipah virus exists other than normal supportive care procedures such as the treatment of the resulting symptoms, rest, and hydration.

Some well-studied antiviral medications like ribavirin, remdesivir, acyclovir, favipiravir, have seen use on a speculative basis during certain outbreaks, but real efficacy is unclear.

Now though, the University of Tokyo’s Research Center for Advanced Science and Technology has developed a potential Nipah virus vaccine by inserting some of the virus’ genetic material into the modified measles vaccine. Early trials in hamsters have shown it to be safe and effective.

Nipah virus fatality rates are 40% to 75%. It’s typically spread by contact between humans and bats, often through people consuming tree fruit contaminated with bat saliva. Once thusly contracted, it can spread quickly through humans via any form of fluid exchange.

The virus is present in the tropics and often in rural areas where access to medical care may be limited.

Tokyo University’s vaccine candidate is now on its way to Belgium for a Phase 1 testing in humans, where with the help of a nonprofit called the European Vaccine Initiative, it will be examined for safety across 60 test candidates.The trials are set to begin in April. Highly Fatal Virus May Finally Be Treatable with First Vaccine–Clinical Trials Starting

Read More........→February 13, 2026

Why do nose and ear hairs become longer and thicker as we age?

Christian Moro, Bond University and Charlotte Phelps, Bond University

Growing older often brings unexpected grooming challenges. This is particularly apparent when some areas that, when young, we could otherwise ignore start to develop hair.

This includes our nose and ears, where hair grows thicker and longer as we age. But why do hairs in these areas act like this?

The answer predominantly lies in our sex hormones.

Two types of hair

There are two types of hair that grows across our bodies.

Vellus hair is fine and colourless. This hair (also called “peach fuzz”) grows across most of our body, including our arms and neck.

Terminal hair is stiff, thick and darker. It stands up from our skin and is usually very obvious. Adult males have terminal hair on about 90% of their body, with females growing it on about 30% of their bodies.

Terminal hair stands up when we’re cold (giving goosebumps) and helps trap heat to keep us warm. It also protects us from the sun (such as hair on our scalp), and keeps dust and dirt out of our eyes through eyebrows and eyelashes.

As vellus hair is smaller, thinner and colourless, it is not usually an aesthetic problem (although it can be altered in some diseases). Instead, it is the terminal hair that is often noticed, and the primary target of our razor.

The normal process of hair development involves a growth phase (anagen), follicle-shrinking phase (catagen), and then a short resting phase (telogen) before the hair falls out and is replaced as the cycle begins again. Some 90% of the hair on our body is in the growth phase at any given time.

Nose, ear, eyelash and eyebrow hairs don’t usually grow too long. This is because the growth phase of the follicles only lasts about 100–150 days, meaning there is a limit to how long they can get.

Alternatively, the hair on your head has a growth phase that lasts several years, so it can grow to more than one meter in length if you don’t get it cut.

Why do we have hair in our nose and ears?

We have about 120 hairs growing in each of our nasal cavities, with an average length of about 1 centimetre.

As you breathe through your nostrils, the hair in your nose works with the mucus to block and collect dust, pollen and other particles that could make their way to your lungs.

The hair in the ears also plays a protective role, trapping foreign objects and working with the earwax to facilitate self-cleaning processes.

What is the effect of ageing?

Androgens are a group of sex hormones that play a key role in puberty, development, and sexual health. The most common androgen is testosterone.

These androgens influence hair growth, and are the key to understanding why we have longer and thicker hairs in our nose and ears.

Hairs in different parts of the body respond to androgens differently. Unlike some hairs that are stimulated at puberty (such as pubic hairs and facial hair in males), some hairs, such as the eyelashes, don’t respond at all to androgens. Others increase hair size much slower, like the ear canal hair that can take up to 30 years.

Females have lower levels of androgens in the body, so major hair growth changes are more localised to the underarms and pubic regions.

We don’t have much data to support various conclusions about hair growth in later life, as most studies have focused on why we lose hair (such as balding) rather than why we have too much.

Nonetheless, there are still some hypotheses about why we grow more ear and nose hair as we age.

1. As we age, the body is exposed to androgens for a long time. This prolonged exposure makes some parts of the body more sensitive to testosterone, potentially stimulating the growth of hairs.

2. Over time, and long-term exposure to testosterone, some of the fine vellus hairs may undergo a conversion and become the darker, longer terminal hairs. This terminal hair then sticks out of our noses and ears.

3. Alongside increased levels of androgens as we go through puberty, a protein called SHBG (sex hormone binding globulin) is also released. This protein helps control the amount of testosterone and estrogen reaching your tissues. During ageing, the levels of SHBG levels may decrease faster than androgens, leaving testosterone to stimulate ear and nose hair growth.

4. Hair simply changes with age. This can result in changes in colour, thinning, and follicle alterations. There might be variations occurring in the follicles that respond to our body’s changing environment, stimulating longer hair growth.

Most of the impact of hairy ears and noses is observed in males, as they have larger amounts of testosterone.

Should we be worried?

It’s not usually a problem. Having a hairy ear (auricular hypertrichosis) does not appear to impact hearing at all. Note that if you are using hearing aids, excessive hair can impact their effectiveness, so in these rarer cases it is worth having a chat with your doctor.

The largest issue appears to be the appearance of these hairs, which can make some people self-conscious.

To address this, avoid plucking hairs out (such as with tweezers), as this can lead to infections, ingrown hairs and inflammation.

Instead, it is safest to reach for the trimmers (or employ laser hair removal processes) to clean up the area a little.

Christian Moro, Associate Professor of Science & Medicine, Bond University and Charlotte Phelps, Senior Teaching Fellow in Medicine, Bond University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read More........→February 12, 2026

Successful World First: Baby Treated with Personalized CRISPR Gene Therapy for Rare Disease is Now ‘Thriving’

Dr. Kiran Musunru (left) and Dr. Rebecca Ahrens-Nicklas (right) led the researchers who developed a personalized treatment for baby KJ – Released CHOP and Penn

CRISPR has been used to create a genetic therapy option for a child born in Pennsylvania with a rare metabolic disorder.

Unable to convert ammonia to urea, newborn KJ was in serious risk of brain or liver damage, and had to be kept on medications and an extremely restrictive diet to avoid protein metabolism.

Children’s Hospital of Philadelphia (CHOP) doctors believed they could use CRISPR to develop a treatment to correct a faulty gene in KJ’s genome that would essentially cure him.

KJ’s parents, Nicole and Kyle Muldoon, decided to place their son’s wellbeing in the hands of two pioneering genetic therapists, Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunru, who crafted a bespoke treatment that has successfully corrected the genetic defect.

“Years and years of progress in gene editing and collaboration between researchers and clinicians made this moment possible, and while KJ is just one patient, we hope he is the first of many to benefit from a methodology that can be scaled to fit an individual patient’s needs,” said Rebecca Ahrens-Nicklas, MD, PhD, director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program (GTIMD) at Children’s Hospital of Philadelphia.

She, along with Dr. Musunru, are members of the NIH-funded Somatic Cell Genome Editing Consortium, and have spent years developing the science of using CRISPR to create individual treatment doses for the rarest of diseases.

So far, the only FDA-approved and standardized CRISPR therapies target two diseases found in tens of thousands of patients. CRISPR is an incredibly complex tool and expensive to wield, leaving its magic beyond the reach of millions of children and adults worldwide who collectively suffer from extremely rare genetic disorders.

One such disorder is called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, and it creates the inability to properly convert ammonia into urea to be excreted through urine. Ammonia is created in the body through protein metabolism. CPS1 is created in the liver to turn it into urea so as to avoid the toxic effects of the former.

KJ’s body cannot, so excess protein metabolism creates a buildup of ammonia in his liver that could be fatal. Nitrogen scavenging medication and a protein-deficient diet can keep a patient going until a liver transplant can be found, but at just months old, KJ’s body isn’t capable of enduring the procedure.

A news release from CHOP reports that Ahrens-Nicklas and Musunuru targeted KJ’s specific variant of CPS1 after years of work with similar disease-causing variants. Within 6 months, their team designed and manufactured a base editing therapy delivered via lipid nanoparticles to the liver in order to correct KJ’s faulty enzyme.

In late February, 2025, KJ received his first infusion of this experimental therapy, and since then has received follow-up doses in March and April 2025, the release details. In the newly published New England Journal of Medicine paper, the researchers, along with their academic and industry collaborators, describe the customized CRISPR gene editing therapy that was rigorously yet speedily developed for administration to KJ.

KJ has received 3 doses, and suffered no side effects. He’s been able to halt medication and work some protein back into his diet, though he will need careful monitoring the rest of his life.“We thought it was our responsibility to help our child, so when the doctors came to us with their idea, we put our trust in them in the hopes that it could help not just KJ but other families in our position,” his mother, Nicole, told CHOP. Successful World First: Baby Treated with Personalized CRISPR Gene Therapy for Rare Disease is Now ‘Thriving’

Read More........→February 06, 2026

IIT Bombay’s new smart platform to help researchers decode brain diseases

(Photo: IIT Bombay) IANS

New Delhi, (IANS) A team of bioengineers at the Indian Institute of Technology (IIT) Bombay has developed new smart platforms --BrainProt and DrugProtAI -- that unify data on scattered brain diseases to help researchers find markers, explore treatments, and pinpoint druggable targets.

BrainProt v3.0 is a database that combines various types of biological data -- from genes to proteins -- into a single platform to enable systematic insights into human brain function in both healthy and diseased states.

It is the first system to integrate multi-disease data from genomics, transcriptomics, proteomics, and biomarker research and multi-database information into one portal.

“BrainProt also includes resources to identify and understand protein expression differences between the left and right hemispheres of the human brain across 20 neuroanatomical regions. This is the first resource of its kind,” said Prof. Sanjeeva Srivastava from the Department of Biosciences and Bioengineering, IIT Bombay.

BrainProt includes data on 56 human brain diseases and 52 multi-omics datasets derived from more than 1,800 patient samples. These datasets include transcriptomic data for 11 diseases and proteomic data for six diseases.

For each disease, users can examine genes and proteins frequently associated with the disease, assess how strongly these genes and proteins are already supported by existing medical and scientific databases, and how their activity levels change in patient samples.

DrugProtAI was developed to understand whether a protein can be druggable (has the biological and physical characteristics needed to be a useful drug target) before doing costly experiments.

This is crucial because only about 10 per cent of human proteins currently have an FDA-approved drug, with another 3-4 per cent under investigation.

“Before investing years of work in a protein target, DrugProtAI predicts whether the protein is druggable by looking beyond the protein’s sequence, such as cellular location, structural attributes, and other unique characteristics it has,” said Dr. Ankit Halder, co-author of the study.

The tool generates a “druggability index” -- a probability score indicating how likely a protein is to be druggable. A higher score suggests that the protein shares many properties with proteins that already have approved drugs, while a lower score indicates that drug development would be more challenging.“By integrating DrugProtAI directly into BrainProt, we created a pipeline where researchers can move from identifying a disease marker to examining its expression patterns to evaluating its druggability and exploring existing compounds or clinical trials, all within an hour,” Halder said. IIT Bombay’s new smart platform to help researchers decode brain diseases | MorungExpress | morungexpress.com

Read More........→January 23, 2026

New Eco-Friendly Tech Eliminates ‘Forever Chemicals’ With Record-Breaking Speed–And it’s Reusable

PFAs self-destruct in this layered double hydroxide material made from copper and aluminum – credit: Rice University

University researchers in Texas and Korea have collaborated to developed an eco-friendly water purifier that captures—and destroys—toxic “forever chemicals” (PFAS) more than 1,000 times better than current methods.

Their study marks a major milestone in addressing one of the world’s most persistent environmental and health threats.

PFAS are synthetic chemicals first created in the 1940s for use in products ranging from Teflon pans to waterproof clothing and food packaging. Their ability to resist heat, grease, and water has made them valuable for industry and consumers, but that same resistance means they do not easily degrade.

Current health studies have suggested their lingering residues in water are linked to possible liver damage, reproductive disorders, immune system disruption, and certain cancers.

Traditional PFAS cleanup methods typically rely on adsorption, where molecules cling to materials like activated carbon or ion-exchange resins. While these methods are widely used, they come with major drawbacks: low efficiency, slow performance, and the creation of additional waste that requires disposal.

“Our new approach offers a sustainable and highly effective alternative,” said Professor Michael Wong at Rice University, who specializes in nanotechnology, chemistry, and biomolecular engineering.

The innovation centers on a layered double hydroxide (LDH) material made from copper and aluminum, first discovered by South Korean Professor Keon-Ham Kim, while he was a grad student at Korea Advanced Institute of Science and Technology in 2021.

While experimenting with these materials, a student at Rice, Youngkun Chung, discovered that one formulation with nitrate could adsorb PFAS with record-breaking efficiency.

“To my astonishment, this LDH compound captured PFAS more than 1,000 times better than other materials,” said Chung, a lead author of the study.

“It also worked incredibly fast, removing large amounts of PFAS within minutes, about 100 times faster than commercial carbon filters.”

The material’s effectiveness stems from its unique internal structure.

Its organized copper-aluminum layers combined with slight charge imbalances create an ideal environment for PFAS molecules to bind—with both speed and strength.

Works equally well in river water, tap water and wastewater

To test the technology’s practicality, the team evaluated the LDH material in river water, tap water and wastewater. In all cases, it proved highly effective, performing well in both static and continuous-flow systems.

The results, recently published in the journal Advanced Materials, suggest strong potential for large-scale applications in municipal water treatment and industrial cleanup.

Closing the waste loop

Removing PFAS from water is only part of the challenge. Destroying them safely is equally important. The team at Rice developed a method to thermally decompose PFAS captured on the LDH material. By heating the saturated material with calcium carbonate, the team eliminated more than half of the trapped PFAS without releasing toxic by-products.

Remarkably, the process also regenerated the LDH, allowing it to be reused multiple times—refreshing itself for reuse.

“It’s a rare one-two punch against pollution,” wrote Science Daily, “fast cleanup and sustainable destruction.”

Preliminary studies showed the material could complete at least six full cycles of capture, destruction and renewal, making it the first known eco-friendly, sustainable system for PFAS removal.

“We are excited by the potential of this one-of-a-kind LDH-based technology to transform how PFAS-contaminated water sources are treated in the near future,” said Professor Wong said.“It’s the result of an extraordinary international collaboration and the creativity of young researchers.” New Eco-Friendly Tech Eliminates ‘Forever Chemicals’ With Record-Breaking Speed–And it’s Reusable

Read More........→January 13, 2026

Time of day may determine heart surgery outcomes: Study

(Photo: AI generated image/IANS)

New Delhi, (IANS) Heart surgery that begins late in the morning may raise the risk of cardiovascular deaths when compared to other times of the day, according to a study.

Researchers at The University of Manchester, UK, suggested that integrating body clock biology into the planning of heart surgery could support a more personalised, precision medicine approach, as some people’s body clock makes them early birds and others make them night owls.

The data, based on the analysis of national datasets comprising over 24,000 patients in England, Wales, and Northern Ireland, showed late-morning surgery was linked to an 18 per cent higher risk of death -- almost one fifth -- from heart-related causes compared with early-morning surgery.

And the most common surgical start time was 07:00 am to 09:59 am -- accounting for 47 per cent of all surgeries.

Though complication rates and readmissions were unaffected by the time of day, the findings still pose questions about the best time to schedule heart surgery.

The study, published in the journal Anaesthesia, also gives an important insight into the potential influence of the body clock -- a set of 24-hour biological cycles present in our cells and organs -- on surgery as a whole.

“This research shows that a slightly higher risk of heart-related mortality is likely to occur when heart surgery starts in the late morning. Even small improvements in timing-related outcomes could have significant benefits to patients,” said lead author Dr Gareth Kitchen, Clinical Senior Lecturer at The University of Manchester.

“However, though the risk is statistically significant, it is relatively modest, and patients can be reassured that most people will almost certainly be unaffected. It is, though, our duty as clinicians to ensure the best possible outcomes, and moderating timings is a potentially inexpensive method to achieve that,” Kitchen added.“With more understanding of how body clock biology varies between individuals, precision and personalised scheduling of cardiac surgery may one day allow us to achieve better patient outcomes,” the researcher said. Time of day may determine heart surgery outcomes: Study | MorungExpress | morungexpress.com

Read More........→January 13, 2026

Mom and Baby Beat 1-in-a-Million Odds to Survive the ‘Rarest of Pregnancies’

This photo provided by the family shows, from left, Kaila, Suze, Ryu and Andrew Lopez at Cedars-Sinai hospital in Los Angeles in August 2025 – family photo

A Los Angeles woman recently celebrated the first Christmas with her baby boy, Ryu, born to truly remarkable circumstances.

Ryu developed outside his mother’s womb, and remained hidden for months behind an ovarian cyst that grew to be the size of a basketball. It was so unbelievable, the surgical/OBGYN team that delivered Ryu documented it for a case study in a medical journal.

The manner in which Ryu came into being represents a circumstance that’s “far, far less than 1 in a million,” said Dr. John Ozimek, medical director of labor and delivery at Cedars-Sinai in Los Angeles, where Ryu was born. “I mean, this is really insane.”

Now 41, Suze Lopez has always had an irregular cycle, so missed periods—even consecutive ones—are a normal occurrence. It was almost 20 years ago that she was diagnoses with a pair of ovarian cysts, one of which was removed immediately, and one of which was not.

So in early 2025 when Lopez noted her abdomen swelling, her first thought was the cyst. She never felt kicking, and never had morning sickness—and indeed her instinct was at least partly correct.

The pressure and pain in her abdomen grew as days passed, and she was certain that, even if it risked her ability to conceive again, it was time to remove the other cyst which unbeknownst to her had grown to weigh a mind-boggling 22 pounds.

She needed a CT scan to prepare for surgery, which required a pregnancy test for the radiation, and to her utter surprise the test came back positive. Lopez was delighted, but the pain and discomfort grew and soon she had to be hospitalized at Cedars-Sinai where her medical team found a near fully-developed fetus in an amniotic sack lodged against her pelvis.

The term for where the fetus develops is “implants” and the term for a fetus that implants outside of the womb is an “ectopic pregnancy.” Almost all of these go on to rupture and hemorrhage. As such, fetal mortality can be as high as 90% in such cases and birth defects are seen in about 1 in 5 surviving babies, SF Gate reports.

However, because fetal Ryu implanted against the pelvic wall and not against the liver, it was far more manageable, and the reason why Lopez didn’t have more pain earlier.

Lopez and her boy beat the odds, despite a mammoth surgical procedure that both delivered Ryu at 8 pounds and removed the ovarian cyst—together weighing as much as an adult bobcat. During the procedure, Lopez lost half her blood, and had to be continually given transfusions.

“The whole time, I might have seemed calm on the outside, but I was doing nothing but praying on the inside,” Andrew Lopez, Suze’s husband, told SF Gate. “It was just something that scared me half to death, knowing that at any point I could lose my wife or my child.”Instead, they both survived without any maleffects. Ryu “completes” their family, said his mother, and recently celebrated his first Christmas alongside his older sister Kaila. Mom and Baby Beat 1-in-a-Million Odds to Survive the ‘Rarest of Pregnancies

Read More........→January 10, 2026

A Rare Cancer-Fighting Plant Compound has Finally Been Decoded

Anti-cancer plant enzyme uncovered by Tuan-Anh Nguyen and Dr Thu-Thuy Dang – UBC Okanagan

Canadian researchers have figured out how plants make a rare natural substance—mitraphylline—with its potential for fighting cancer and becoming a sustainable new medicine.

Mitraphylline is part of a small and unusual family of plant alkaloids, molecules that are defined by their distinctive twisted ring shapes, which help give them powerful anti-tumor and anti-inflammatory effects.

For years, scientists knew these compounds were valuable but had little understanding of how plants actually assembled them at the molecular level.

In solving a long standing biological mystery, progress came in 2023, when a research team led by Dr. Thu-Thuy Dang at the University of British Columbia-Okanagan identified the first known plant enzyme capable of creating the signature ‘spiro’ shape found in these molecules.

Building on that discovery, doctoral student Tuan-Anh Nguyen led new work to pinpoint two key enzymes involved in making mitraphylline—one enzyme that arranges the molecule into the correct three dimensional structure, and another that twists it into its final form.

“This is similar to finding the missing links in an assembly line,” says Dr. Dang, the university’s Research Chair in Natural Products Biotechnology. “It answers a long-standing question about how nature builds these complex molecules and gives us a new way to replicate that process.”

Red vein kratom leaves by Jade at Thehealingeast – CC BY-SA 4.0

Many promising natural compounds exist only in extremely small quantities within plants, making them expensive or impractical to produce using traditional laboratory methods. Mitraphylline is a prime example. It appears only in trace amounts in tropical coffee trees such as Mitragyna (kratom) and Uncaria (cat’s claw).

By identifying the enzymes that construct and shape mitraphylline, scientists now have a clear guide for recreating this process in more sustainable and scalable ways.

Toward Greener Drug Production

“With this discovery, we have a green chemistry approach to accessing compounds with enormous pharmaceutical value,” says Nguyen. “This is a result of UBC Okanagan’s research environment, where students and faculty work closely to solve problems with global reach.”

“Plants are fantastic natural chemists,” Dr. Dang said.

“Our next steps will focus on adapting their molecular tools to create a wider range of therapeutic compounds.”“Being part of the team that uncovered the enzymes behind spirooxindole compounds has been amazing,” added Nguyen, whose team collaborated with researchers at the University of Florida. A Rare Cancer-Fighting Plant Compound has Finally Been Decoded

Read More........→January 08, 2026